ArticleJournal, genetic engineering & biotechnology2025
Designing siRNAs against non-structural genes of all serotypes of Dengue virus using RNAi technology - A computational investigation.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNAi-based therapeutics targeting the F gene in human metapneumovirus: An in-silico approach.Journal, genetic engineering & biotechnology · 2026Article
- Structure-guided identification of a potential inhibitor targeting the VacA toxin of Helicobacter pylori.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a viral disease caused by Aedes aegypti and Aedes albopictus mosquitoes, leads to severe health complications, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The disease has intensified in Asian countries such as Bangladesh, India, Myanmar, and Thailand, with regular outbreaks since 2015, partly due to the lack of effective vaccines or treatments against this ferocious virus. Nonstructural (NS) genes of Dengue virus (DENV) are believed to play vital role in viral replication. Targeting the NS genes of existing serotypes of DENV, we aimed to design a potential small interfering RNA (siRNA) that has the capability to silence the NS genes hence, provide a ground strategy for antiviral therapeutics. In this investigation, a comprehensive computational approach encompassing data collection from NCBI database, GC content analysis, conservation prediction across all DENV serotypes, mRNA-siRNA duplex thermodynamic assessment, siRNA efficacy evaluation, molecular modeling and structural refinement, molecular docking were performed. These analyses anticipated three efficient siRNAs (S2, S3 and S11) that could have the capability to silence all the NS protein-coding genes employed by the DENV. Based on additional analysis including molecular dynamic (MD) simulation, principal component analysis (PCA) and free energy landscape (FEL), two siRNAs (S2 and S11) were recommended as potential therapeutics that could effectively degrade viral NS protein-coding genes through the RNAi pathway. However, S2 (Guide: 5'-UGUUUUUCGCCUUUUUCCGUU-3' and Passenger: 5'- CGGAAAAAGGCGAAAAACACG-3') molecule is supposed to be appeared the most promising siRNA compared to S11. This study is the foundational contribution enabling chemically synthesized future antiviral drug discovery for combating DENV, especially in the Asian region where frequent outbreaks are common. Nonetheless, in vivo validation and further evaluations are necessary before these siRNAs can be advanced as molecular therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.